EP Patent

EP0378255A2 — 2-Aminopyrimidinone derivatives

Assigned to Janssen Pharmaceutica NV · Expires 1990-07-18 · 36y expired

What this patent protects

Novel 2-aminopyrimidinone derivatives of formula wherein R¹ is R³ is hydrogen or C₁₋₆alkyl; R⁴ is hydrogen, C₁₋₆alkyl or substituted C₁₋₆alkyl; R⁵ is hydrogen, C₁₋₆alkyl, C₁₋₆alkylaminocarbonyl, Ar-aminocarbonyl, C₁₋₆alkylcarbonyl or Ar-carbonyl; R⁶ is hydrogen, C₁…

USPTO Abstract

Novel 2-aminopyrimidinone derivatives of formula wherein R¹ is R³ is hydrogen or C₁₋₆alkyl; R⁴ is hydrogen, C₁₋₆alkyl or substituted C₁₋₆alkyl; R⁵ is hydrogen, C₁₋₆alkyl, C₁₋₆alkylaminocarbonyl, Ar-aminocarbonyl, C₁₋₆alkylcarbonyl or Ar-carbonyl; R⁶ is hydrogen, C₁₋₆alkyl or Ar-C₁₋₆alkyl; or R⁵ and R⁶ taken together is -CH₂-CH₂-, -CH₂-CH₂-CH₂-, -CH=CH-, -CH=N-, -N=CH- or -N=CH-CH₂-; the pharmaceutically acceptable acid addition salts and possible stereochemically isomeric forms thereof; pharmaceutical compositions containing such compounds as an active ingredient and methods of preparing said compounds and pharmaceutical compositions.

Drugs covered by this patent

Patent Metadata

Patent number
EP0378255A2
Jurisdiction
EP
Classification
Expires
1990-07-18
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Pharmaceutica NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.